News Daily News Shock’s Added Risk in Acute MI Restricted to the First Few Months After Discharge Caitlin E. Cox February 16, 2016
News Daily News Comparative Analysis Suggests ACE Inhibitors Equivalent to ARBs in Patients Without Heart Failure Michael O'Riordan January 19, 2016
News Daily News Perioperative Statin Therapy Improves Clinical Outcomes Following CABG Surgery Michael O'Riordan January 17, 2016
News Daily News Calculator Developed to Predict AKI Risk After Angiography in VA Population Caitlin E. Cox December 29, 2015
News Daily News Many Lower-Income Patients Fail to Stick With Clopidogrel After PCI Todd Neale December 10, 2015
News Daily News AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients L.A. McKeown December 09, 2015
News Conference News AHA 2015 PROMISE Analyses: Coronary CTA May Hold Some Benefits for Patients With Suspected CAD Todd Neale November 10, 2015
News Conference News AHA 2015 SPRINT Makes Case for Even Lower BP Target in Many Hypertensive Patients Todd Neale November 08, 2015
News Daily News No Money, No Drugs: Global Barriers to Secondary CVD Prevention Caitlin E. Cox October 27, 2015
News Daily News Revascularization May Benefit Stable CAD Patients With Unclassifiable Appropriateness Scores Todd Neale October 08, 2015
News Daily News Registry Study Links CTO PCI to Improved Survival vs Medical Therapy, CABG September 17, 2015
News Conference News ESC 2015 High-Sensitivity Troponin Assay Use Does Not Appear to Increase Diagnostic Procedures L.A. McKeown September 02, 2015
News Industry News Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure August 31, 2015
News Daily News Cardiac Rehab After Acute MI Linked to Improved Survival, Medication Adherence Leah Lawrence August 30, 2015
News Daily News FDA Approves Heart Failure Drug That Comes With Survival Benefit Todd Neale July 13, 2015
News Industry News Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan) July 07, 2015
News Industry News Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions June 05, 2015